Zealand chief medical officer on abandoned Boehringer collaboration: "We need to look at the data"

Boehringer Ingelheim called off a collaboration to develop amylin analog drugs for obesity and diabetes with Zealand Pharma on Friday. Zealand must now decide whether to develop an amylin analog itself, or scrap the project.

Adam Steensberg, chief medical officer at Zealand Pharma. Photo: Zealand Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles